{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-002478","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.443638+00:00","generated_at":"2026-05-16T09:28:00.374345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M","bullets":["Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).","Gross margin improved to ~22% in Q4, up from 14% in Q3 2025.","Q4 cash flow from operations ~$2.3M, second cash-positive quarter; cash & equivalents ~$25M at year-end.","CEO highlighted revenue growth, increased profitability, and portfolio diversification as 2026 focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-002478","json":"https://secwatch.observer/filing/0001628280-26-002478.json","markdown":"https://secwatch.observer/filing/0001628280-26-002478.md","text":"https://secwatch.observer/filing/0001628280-26-002478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026002478/0001628280-26-002478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828026002478/rmti-20260120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:28:00.374345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}